P2345 - Serum Lysosomal Acid Lipase Activity as a Potential Non-Invasive Diagnostic Marker for Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis

Azizullah Beran, MD¹, Renato Beas, MD¹, Mouhand FH. Mohamed, MD², Alejandra Vargas, MD³, Tarek Aboursheid, MD⁴, Fouad Jaber, MD⁵, Saqr Alsakarneh, MD⁵, Khaled Elfert, MD⁶, Sarah Yates, DO¹, Syed Hamaad Rahman, DO⁷, Eleazar E.. Montalvan-Sanchez, MD^8
1Indiana University, Indianapolis, IN; ²Brown University, Providence, RI; ³Eastern Virginia Medical School, Norfolk, VA; ⁴Ascension Saint Francis Hospital, Chicago, IL; ⁵University of Missouri-Kansas City, Kansas City, MO; ⁶SBH Health System, Bronx, NY; ⁷Methodist Dallas Medical Center, Dallas, TX; ⁸Indiana University School of Medicine, Indianapolis, IN

Introduction: Non-alcoholic fatty liver disease (NAFLD) is characterized by intra-hepatic fat accumulation, and the mechanisms involved in its pathogenesis are not fully understood. Serum Lysosomal Acid Lipase (LAL) is an essential enzyme involved in lipid metabolism, and its activity has been proposed as a novel mechanism contributing to the disease. We conducted a systematic review and meta‐analysis to compare LAL activity levels in patients with NAFLD and patients without NAFLD.

Methods: We conducted an extensive literature search using PubMed, EMBASE, and Web of Science databases through April 2023 for all published studies that reported LAL activity levels in patients with NAFLD and patients without NAFLD. Continuous variables (using mean serum levels and standard deviation) were compared, and mean difference (MD) was estimated with a 95% confidence interval (CI), and a P value < 0.05 was considered statistically significant. Meta-analyses were performed using a random-effect model with the inverse variance method.

Results: A total of six studies involving 1,608 patients were included. A comparison of mean LAL activity levels for NAFLD and non-NAFLD patients was performed in all six studies. The pooled mean LAL activity level was 0.80 ± 0.34 and 1.09 ± 0.54 ng/ml for NAFLD and non-NAFLD patients, respectively. The pooled mean LAL activity level was significantly lower in NAFLD patients than in non-NAFLD patients (MD -0.29; 95% CI -0.46, -0.12; P< 0.001, I²=96%; Figure 1A). A leave-one-out sensitivity analysis showed consistent results (Figure 1B).

Discussion: Our meta-analysis demonstrates a significant association between reduced LAL activity and NAFLD incidence. LAL activity may serve as a new non-invasive diagnostic marker to identify patients with NAFLD. Further studies with larger sample sizes, especially in NAFLD patients without genetic causes, are needed to validate our findings.



Disclosures:


Azizullah Beran, MD¹, Renato Beas, MD¹, Mouhand FH. Mohamed, MD², Alejandra Vargas, MD³, Tarek Aboursheid, MD⁴, Fouad Jaber, MD⁵, Saqr Alsakarneh, MD⁵, Khaled Elfert, MD⁶, Sarah Yates, DO¹, Syed Hamaad Rahman, DO⁷, Eleazar E.. Montalvan-Sanchez, MD⁸. P2345 - Serum Lysosomal Acid Lipase Activity as a Potential Non-Invasive Diagnostic Marker for Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis, ACG 2023 Annual Scientific Meeting Abstracts. Vancouver, BC, Canada: American College of Gastroenterology.